The United States National Institutes of Health (NIH) signed a deal today with the World Health Organization’s COVID-19 Technology Access Pool (C-TAP) and the Medicines Patent Pool (MPP) that allows manufacturers greater access to key COVID-19 technologies owned by NIH. The licensing agreement offers 11 technologies under transparent, global and non-exclusive licenses. They include “the stabilized spike protein used in currently available COVID-19 vaccines, research tools for vaccine, therapeutic and diagnostic development as well as early-stage vaccine candidates and diagnostics.”
Recent Posts
- IPWatchdog Masters Panelists Urge U.S. Government to Get Organized When It Comes to AI
- Fixing the PTAB: 10 Things the USPTO Can Do to Improve the PTAB | IPWatchdog Unleashed
- Fox Succeeds in Scrapping Machine Learning Claims at CAFC Under 101
- Other Barks & Bites for Friday, April 18: CAFC Affirms Ineligibility of Machine Learning Claims; EPO’s Campinos Issues Opinion on Intervener Appeals; USPTO Ends Climate Change Mitigation Program
- In Latest Antitrust Blow for Google, Judge Finds Search Giant Monopolizes Certain Ad Tech Markets